Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Orchard Therapeutics PLC (ORTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Orchard's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Orchard historical data, for real-time data please try another search
16.700 +0.000    +0.00%
23/01 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 16.635 - 16.720
Orchard 16.700 +0.000 +0.00%

NASDAQ:ORTX Financials

 
A brief overview of the NASDAQ:ORTX financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Orchard Therapeutics PLC over time.

Orchard Therapeutics plc reported earnings results for the third quarter ended September 30, 2023. For the third quarter, the company reported revenue was USD 6.3 million compared to USD 5.78 million a year ago. Net loss was USD 35.32 million compared to USD 47.57 million a year ago. Basic loss per share from continuing operations was USD 1.5 compared to USD 3.7 a year ago. Diluted loss per share from continuing operations was USD 1.5 compared to USD 3.7 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ORTX Income Statement

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 6.3 7.31 1.24 6.99
Gross Profit -10 -11.57 -15.12 -20.99
Operating Income -21.6 -22.56 -26.26 -31.59
Net Income -35.32 -12.31 -17.41 -7.88

ORTX Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 202.27 232.3 217.02 218.91
Total Liabilities 122.01 123.26 115.36 120.64
Total Equity 80.26 109.05 101.66 98.26

ORTX Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -48.38%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -23.89 -27.83 -29.51 -12.08
Cash From Investing Activities 11.58 -26.69 -9.35 -1.56
Cash From Financing Activities -2.35 30.94 31.51 -0.811
Net Change in Cash -14.8 -23.21 -6.94 -12.38
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ORTX Comments

Write your thoughts about Orchard Therapeutics PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giuseppe Giannachi
Giuseppe Giannachi Feb 16, 2021 10:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What's going on?
Joe Jordan
Joe Jordan Feb 13, 2021 6:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any target price?
Alpha Master
Alpha Master Feb 13, 2021 6:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I like the Co. But don't trust its CEO, no transparent at all levels and high dilution possibilities
Joe Jordan
Joe Jordan Feb 05, 2021 1:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has executed a securities purchase agreement to raise gross proceeds of $150 Million
Joe Jordan
Joe Jordan Jan 06, 2021 5:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Hakan YILMAZ
Hakan YILMAZ Dec 21, 2020 5:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Hisham Mashari
Hisham Mashari Oct 22, 2020 1:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sky is the limit.. Head and shoulders are clear
Faisal Almohanna
Faisal Almohanna Oct 20, 2020 8:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think ORTX is headed towards record highs after the EMA new approvals. We can easily see it trading at $16 very soon according to couple of sell side research reports.
Faisal Almohanna
Faisal Almohanna Oct 20, 2020 8:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think its flying to $16 very soon
Alpha Master
Alpha Master Oct 03, 2020 5:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any hope for this crippled stock?
Joe Jordan
Joe Jordan Dec 23, 2019 4:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Any target price?
Abdul Bath
Abdul Bath Dec 23, 2019 4:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
4.84
IDAN PARNES
IDAN PARNES Dec 23, 2019 4:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
16$ at dec 2021
Mohamed Shabaan
Mohamed Shabaan Dec 23, 2019 4:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email